Kringle Pharma is a late clinical-stage biopharmaceutical company
aiming to provide new medicines to patients and bring
a smile to people’s faces.
Research and Development
We will contribute to our society and global health by research,
development and commercialization of innovative medicines for patients suffering from incurable diseases.
Kringle Pharma is a late clinical-stage biopharmaceutical company.
Currently, we are conducting clinical trials of HGF protein, which is a regenerative drug candidate, for the treatment of rare and intractable diseases.
Our strength is that we have a proprietary platform for manufacturing HGF protein in pharmaceutical grade. While maintaining the basic policy of in-house development and sales model, we will build a unique business model that combines out-licensing, co-development and API supply models to maximize profits over the medium to long term.